ArriVent BioPharma (AVBP) Competitors

$26.15 -0.89 (-3.29%)

Closing price 04:00 PM Eastern

Extended Trading

$26.17 +0.02 (+0.08%)

As of 04:10 PM Eastern

AVBP vs. GRFS, APLS, APGE, CRSP, and DNTH

Should you buy ArriVent BioPharma stock or one of its competitors? MarketBeat compares ArriVent BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ArriVent BioPharma include Grifols (GRFS), Apellis Pharmaceuticals (APLS), Apogee Therapeutics (APGE), CRISPR Therapeutics (CRSP), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry.

How does ArriVent BioPharma compare to Grifols?

ArriVent BioPharma (NASDAQ:AVBP) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Grifols has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Grifols	$8.51B	0.63	$454.82M	$0.19	41.26

ArriVent BioPharma presently has a consensus price target of $42.78, indicating a potential upside of 63.59%. Grifols has a consensus price target of $10.00, indicating a potential upside of 27.55%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, research analysts clearly believe ArriVent BioPharma is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

9.5% of ArriVent BioPharma shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Grifols has a net margin of 5.54% compared to ArriVent BioPharma's net margin of 0.00%. Grifols' return on equity of 6.21% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Grifols	5.54%	6.21%	2.39%

ArriVent BioPharma has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, Grifols has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

In the previous week, ArriVent BioPharma had 8 more articles in the media than Grifols. MarketBeat recorded 10 mentions for ArriVent BioPharma and 2 mentions for Grifols. Grifols' average media sentiment score of -0.17 beat ArriVent BioPharma's score of -0.34 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ArriVent BioPharma beats Grifols on 8 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to Apellis Pharmaceuticals?

ArriVent BioPharma (NASDAQ:AVBP) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

ArriVent BioPharma currently has a consensus target price of $42.78, suggesting a potential upside of 63.59%. Apellis Pharmaceuticals has a consensus target price of $35.72, suggesting a potential downside of 12.94%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe ArriVent BioPharma is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09

Apellis Pharmaceuticals has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Apellis Pharmaceuticals	$1.11B	4.75	$22.39M	$1.02	40.23

In the previous week, ArriVent BioPharma had 4 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 10 mentions for ArriVent BioPharma and 6 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.00 beat ArriVent BioPharma's score of -0.34 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apellis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apellis Pharmaceuticals has a net margin of 12.06% compared to ArriVent BioPharma's net margin of 0.00%. Apellis Pharmaceuticals' return on equity of 39.71% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Apellis Pharmaceuticals	12.06%	39.71%	13.20%

ArriVent BioPharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, Apellis Pharmaceuticals has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market.

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by company insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Apellis Pharmaceuticals beats ArriVent BioPharma on 8 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, ArriVent BioPharma had 7 more articles in the media than Apogee Therapeutics. MarketBeat recorded 10 mentions for ArriVent BioPharma and 3 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.18 beat ArriVent BioPharma's score of -0.34 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apogee Therapeutics' return on equity of -32.64% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Apogee Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

Apogee Therapeutics presently has a consensus price target of $112.73, indicating a potential upside of 43.77%. ArriVent BioPharma has a consensus price target of $42.78, indicating a potential upside of 63.59%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Apogee Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Summary

Apogee Therapeutics and ArriVent BioPharma tied by winning 6 of the 12 factors compared between the two stocks.

How does ArriVent BioPharma compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

ArriVent BioPharma has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
ArriVent BioPharma	N/A	-48.98%	-45.44%

ArriVent BioPharma has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,307.71	-$581.60M	-$6.22	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

CRISPR Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CRISPR Therapeutics currently has a consensus target price of $65.47, indicating a potential upside of 37.57%. ArriVent BioPharma has a consensus target price of $42.78, indicating a potential upside of 63.59%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, ArriVent BioPharma had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 10 mentions for ArriVent BioPharma and 5 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.66 beat ArriVent BioPharma's score of -0.34 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ArriVent BioPharma beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to Dianthus Therapeutics?

ArriVent BioPharma (NASDAQ:AVBP) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, ArriVent BioPharma had 5 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 10 mentions for ArriVent BioPharma and 5 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.33 beat ArriVent BioPharma's score of -0.34 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ArriVent BioPharma has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Dianthus Therapeutics has higher revenue and earnings than ArriVent BioPharma. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Dianthus Therapeutics	$2.04M	2,295.87	-$162.34M	-$4.13	N/A

ArriVent BioPharma currently has a consensus price target of $42.78, indicating a potential upside of 63.59%. Dianthus Therapeutics has a consensus price target of $117.82, indicating a potential upside of 37.53%. Given ArriVent BioPharma's higher probable upside, research analysts clearly believe ArriVent BioPharma is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

ArriVent BioPharma has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Summary

Dianthus Therapeutics beats ArriVent BioPharma on 8 of the 14 factors compared between the two stocks.

Get ArriVent BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVBP vs. The Competition

Export

Metric	ArriVent BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.26B	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	N/A	18.70	20.58	25.09
Price / Sales	N/A	278.20	577.42	91.07
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	3.76	6.57	9.68	6.60
Net Income	-$166.31M	$24.30M	$3.55B	$335.71M
7 Day Performance	-9.73%	-3.56%	-2.07%	-2.03%
1 Month Performance	-11.77%	-7.86%	-3.90%	-1.90%
1 Year Performance	35.14%	51.80%	29.39%	27.36%

ArriVent BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVBP ArriVent BioPharma	2.5896 of 5 stars	$26.15 -3.3%	$42.78 +63.6%	+39.7%	$1.26B	N/A	N/A	40
GRFS Grifols	3.9737 of 5 stars	$7.56 -3.1%	$10.00 +32.3%	+1.4%	$5.31B	$8.51B	39.79	25,247	Analyst Downgrade
APLS Apellis Pharmaceuticals	1.3182 of 5 stars	$41.06 +0.1%	$35.72 -13.0%	+135.1%	$5.25B	$1.00B	40.26	770	Analyst Upgrade
APGE Apogee Therapeutics	2.4756 of 5 stars	$82.93 -2.0%	$112.73 +35.9%	+93.9%	$5.23B	N/A	N/A	91
CRSP CRISPR Therapeutics	3.2324 of 5 stars	$52.83 -2.2%	$66.06 +25.0%	+25.3%	$5.21B	$3.51M	N/A	460

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVBP) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ArriVent BioPharma (AVBP) Competitors

AVBP vs. GRFS, APLS, APGE, CRSP, and DNTH

How does ArriVent BioPharma compare to Grifols?

Summary

How does ArriVent BioPharma compare to Apellis Pharmaceuticals?

Summary

How does ArriVent BioPharma compare to Apogee Therapeutics?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Summary

How does ArriVent BioPharma compare to Dianthus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ArriVent BioPharma (AVBP) Competitors

AVBP vs. GRFS, APLS, APGE, CRSP, and DNTH

How does ArriVent BioPharma compare to Grifols?

Which has higher valuation and earnings, AVBP or GRFS?

Do analysts prefer AVBP or GRFS?

Do institutionals and insiders have more ownership in AVBP or GRFS?

Is AVBP or GRFS more profitable?

Which has more risk and volatility, AVBP or GRFS?

Does the media prefer AVBP or GRFS?

Summary

How does ArriVent BioPharma compare to Apellis Pharmaceuticals?

Do analysts rate AVBP or APLS?

Which has stronger earnings & valuation, AVBP or APLS?

Does the media prefer AVBP or APLS?

Is AVBP or APLS more profitable?

Which has more volatility and risk, AVBP or APLS?

Do insiders & institutionals hold more shares of AVBP or APLS?

Summary

How does ArriVent BioPharma compare to Apogee Therapeutics?

Does the media favor APGE or AVBP?

Is APGE or AVBP more profitable?

Which has more volatility and risk, APGE or AVBP?

Do analysts recommend APGE or AVBP?

Do insiders and institutionals have more ownership in APGE or AVBP?

Which has higher earnings and valuation, APGE or AVBP?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Is CRSP or AVBP more profitable?

Which has preferable valuation and earnings, CRSP or AVBP?

Which has more volatility & risk, CRSP or AVBP?

Do institutionals & insiders have more ownership in CRSP or AVBP?

Do analysts prefer CRSP or AVBP?

Does the media favor CRSP or AVBP?

Summary

How does ArriVent BioPharma compare to Dianthus Therapeutics?

Does the media refer more to AVBP or DNTH?

Do institutionals and insiders have more ownership in AVBP or DNTH?

Is AVBP or DNTH more profitable?

Which has better valuation and earnings, AVBP or DNTH?

Do analysts rate AVBP or DNTH?

Which has more risk & volatility, AVBP or DNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools